ReviewFrontiers in immunology2026
Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal carcinoma (EC) remains one of the most lethal malignancies, with a five-year survival rate of only 15-25% in advanced stages. Although immunotherapy including immune checkpoint inhibitors (ICIs) and antibody-based therapies have improved clinical outcomes, durable responses are confined to a minority of patients because primary and acquired resistance affect the majority. The tumor microenvironment (TME)-composed of immune cells, stromal cells, and the extracellular matrix-has emerged as a central driver of the immune resistance, wherein infiltrating immune cells and stromal cells form suppressive networks that impair cytotoxic immunity and foster tumor progression. However, a coherent framework linking clinical practice, TME-mediated resistance mechanisms, and therapeutic strategies remains lacking. In this review, we dissect the cellular and molecular basis of TME-driven immune resistance in EC, summarize established and emerging immunotherapies, and evaluate strategies to overcome treatment failure, including TME-targeted therapy, metabolic modulation, photodynamic therapy, and mechanism-guided combination approaches. These insights reframe immunotherapy resistance as a TME-driven process rather than a purely tumor-intrinsic defect, underscoring the need to concurrently target malignant cells and their surrounding immunosuppressive niche. Ultimately, elucidating TME heterogeneity and its dynamic evolution is essential to convert resistant EC into an immunotherapy-responsive disease and to guide precision combination strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.